{"entity":{"id":"nct07326488","kind":"trial","name":"A Study of MHB009C in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of MHB009C for Injection in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.","summary":"A Study of MHB009C in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07326488 by Minghui Pharmaceutical (Hangzhou) Ltd, with 200 participants planned, started 2026-03-17 and due to reach its primary completion in 2028-02. Interventions recorded: MHB009C for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07326488","url":"https://clinicaltrials.gov/study/NCT07326488"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07326488","phase":"1/2","setting":"A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MHB009C for Injection in Patients With Advanced Solid Tumors","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","enrolled":200,"outcomes":[]},"route":"/trials/nct07326488/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}